ABSTRACT Background: Obesity, defined by body mass index (BMI), appears to have a paradoxical protective effect in several chronic diseases. Objective: We investigated the obesity paradox in cancer patients by using body composition. Design: The study was an observational study of 175 cancer patients assessed before chemotherapy. Obesity was defined as BMI (in kg/m 2 ) $30 or fat mass index (FMI; fat mass divided by the square of height) $5.2 (men) and $8.2 (women) measured by using a bioelectrical impedance analysis. Low muscle mass (sarcopenia) was defined as fat-free mass index (fat-free mass divided by the square of height) ,17.5 (men) and ,15.1 (women). Results: Most patients were women (65.7%) and had a mean (6SD) age of 56.9 6 12.8 y. According to BMI criteria, 60% of patients were overweight or obese. The median survival time for overweight (2.64 y; range: 0.23-3.16 y) and obese (2.61 y; range: 0.26-3.20 y) patients was significantly higher than for patients with a normal (2.04 y; range: 0.06-3.05 y) or low (0.52 y; range: 0.19-0.98 y) BMI (P , 0.001). Sarcopenic patients had shorter survival, regardless of their FMI. Obesity predicted higher survival rates only when sarcopenia was absent. In a multivariate Cox regression model, sarcopenia was an independent predictor of higher mortality (HR: 5.19; 95% CI: 2.58, 10.43) after we controlled for BMI, age, and tumor stage. Conclusions: The obesity paradox is present in cancer patients only when obesity is defined by BMI. Patients with sarcopenic obesity had the poorest prognosis. Cancer patients with high mortality risk can be identified by a body-composition assessment.
INTRODUCTION
Cancer is one of the leading causes of death around the world. According to the WHO, 15.5 million new cancer cases will be diagnosed by 2030, with an estimated 11.5 million cancer deaths, which is an increase of 45% in cancer deaths from 2007 (1) .
Cancer can have an important impact on a patient's nutritional status, including the development of cachexia as the most severe clinical form of energy-protein imbalance. Cachexia is a multifactorial syndrome that includes a loss of skeletal muscle mass, accompanied in some cases with a loss of fat mass (FM) 4 . Cancer cachexia cannot be fully reversed by conventional nutritional therapy and leads to progressive functional impairment, reduced tolerance to cancer treatments, and poor survival (2) . Cachexia represents a cause of death, either by direct or indirect mechanisms, in one-third of cancer patients (3) .
Weight loss and cachexia are well-defined morbidity and mortality risk factors in cancer patients (2, 4) . A possible common mechanism shown in these 2 conditions is the depletion of body protein mass (ie, muscle loss). This muscle loss can lead to sarcopenia, depending on the combination of the following 2 factors: previous stores of body protein mass and the severity of depletion. The major implication of this condition is that anthropometric measurements and BMI cannot always easily identify this loss (2) .
Although obesity is considered an important risk factor for the development of chronic conditions, including several types of cancer, the presence of obesity appears to be a paradoxical protective factor for survival in patients with cardiovascular disease, chronic renal failure, chronic pulmonary obstructive disease, AIDS, and rheumatoid arthritis (5) (6) (7) (8) (9) .
Opponents of this reverse epidemiology have suggested that better preillness health care for obese patients and the occurrence of acute cardiovascular events at early ages are associated with a consequent longer age-related survival benefit.
One possible explanation for the obesity paradox is the diagnosis of obesity on the basis of BMI (in kg/m 2 ) $30 (5). Because BMI does not accurately differentiate between lean compared with fat tissues, it is unable to depict the independent prognostic effect of each individual tissue. In other words, BMI does not provide information on whether excess FM, excess lean mass, or an excess of both masses provides a survival benefit in these patients (10) . The advent of technology such as bioelectrical impedance analysis (BIA) allows for a body composition assessment in clinical studies with an improved understanding of the prognostic effect of each body compartment. In the current study, we use BIA-derived body composition measurements to explore the underlying basis of the obesity paradox in patients with cancer at the start of their chemotherapy program.
SUBJECTS AND METHODS
Patients who started a course of chemotherapy for the first time between March and December 2004 were prospectively evaluated. The project was approved by the Ethics Committee in Research of the University Hospital, Federal University of Pelotas, Brazil.
Patients were invited to take part in the study if they were $18 y old, were receiving chemotherapy for the first time, and could rest quietly in a recumbent position for the BIA examination. The presence of a pacemaker, clinical conditions that would prevent patients from receiving chemotherapy, and the presence of edema were considered exclusion criteria.
All clinical and demographic data were collected before the first chemotherapy course. Data related to the patient's illness were obtained from the hospital's electronic medical record system. Body weight was measured with a digital scale (PL 150, accuracy of 6100 g; Filizola). Height was measured with a standardized technique by using a 200-cm metal tape measure with an accuracy of 1 mm. BMI was estimated as weight divided by the square of height. Patients were classified according to BMI as underweight (BMI ,18.5), normal (BMI between 18.5 and 24.9), overweight (BMI between 25 and 29.9), or obese (BMI $30).
Nutritional status was assessed by using the patient-generated subjective global assessment, and patients were classified as well nourished (A), moderately (or suspected of being) malnourished (B), or severely malnourished (C) (11) . Body composition was evaluated by using a Quantum 101 BIA (RJL Systems) according to a standardized technique. Resistance and reactance were measured in ohms at 50 kHz and 800 mA. Three measurements of resistance and reactance were obtained, and the lowest value was applied to Vcorp software (CompCorp I.E.C.S.) to assess fat-free mass (FFM) and FM.
The fat-free mass index (FFMI) and fat mass index (FMI) were calculated by using the following equations:
FFMI and FMI cutoffs suggested by Kyle et al (12) were used to define high FM and low FFM as shown in Table 1 . Patients were also classified in groups according to the combination of their FFM and FM compartments as follows: a low FFMI and high FMI (group 1: sarcopenic obesity), a normal FFMI and high FMI (group 2: obesity), a normal FFMI and FMI (group 3: normal), and a low FFMI and normal FMI (group 4: sarcopenia).
The sample size was estimated from other studies to detect a difference $5% in body weight and phase angle between prechemotherapy and postchemotherapy treatment (13, 14) . Patients were followed for 36 mo after inclusion in the study. A patient's survival was calculated as the time interval between the first examination and the patient's date of death (as a result of any cause) or the date lost during follow-up.
Anthropometric and body-composition data were collected by a previously trained dietitian and were validated after double typing with EpiInfo 6 software (CDC). Statistical analyses were conducted with Stata 9.2 software (StataCorp LP). The KaplanMeier method was used to estimate the survival function, and the log-rank test was used to evaluate the difference between survival curves. Survival curves were generated within BMI, FFMI, and FMI categories.
Cox regression was used to determine the independent and combined effects of the FFMI and FMI on the patient's survival, with adjustment for possible confounders such as age, sex, and tumor location and stage. All variables were tested in a univariate analysis, and only variables with P values ,0.05 were considered significant after the multivariate Cox regression, although all variables with a P value ,0.2 were kept in the final model. In all tests, a P value ,0.05 was considered significant. Table 2 . The study included 175 patients (65.7% women) with a mean (6SD) age of 56.9 6 12.8 y. The most prevalent tumor location was the breast (50.8%) followed by head, neck, and gastrointestinal locations (26.3%). Fifty-four percent of patients presented with advanced disease (stage III or IV). Sixty percent of patients were overweight or obese (BMI $25), and 76.6% of patients were classified as well nourished (patient-generated subjective global assessment A). The prevalence of obesity differed according to BMI or FMI diagnostic criteria. According to BMI, only 26% of patients were classified as obese. In contrast, sex-specific FMI criteria identified an overall prevalence of obesity in 59% of the cohort. When both FMI and FFMI cutoffs were used, 58% of patients were classified as obese, and 1% of patients were classified as presenting with a concurrent high FMI and low FFMI (ie, sarcopenic obese). When the FMI was used as the reference, BMI showed a 1% rate of false-positive results (ie, BMI $30 but normal FMI) but 56% false-negative results (ie, BMI ,30 with high FMI). As illustrated in Figure 1 , only 69% of patients with normal BMI presented with a normal body composition (normal FFMI and FMI). All patients with sarcopenic obesity, 81% of patients with sarcopenia only, and 5% of patients with obesity only were misclassified as presenting with normal BMI.
RESULTS

Characteristics of patients are shown in
Sixty-seven patients (38.3%) died during the study period. The median survival time according to BMI or body composition is shown in Table 3 . Survival curves according to BMI categories are shown in Figure 2A . Obese and overweight patients had significantly longer survival times than did patients with BMI ,25 (P , 0.001). Patients with a low FFMI ( Figure 2B ) had a significantly shorter median survival (0.47 y; range: 0.06-2.98 y) than that of patients with a normal or high FFMI (2.59 y; range: 0.23-3.20 y; P , 0.001). Over 6 mo, 50% of patients with a low FFMI had already died; at the end of the 3-y follow-up period, 68% of patients with a normal FFMI remained alive. When patients were analyzed according to their body fat (FMI), patients with high FMI ( Figure 2C ) presented with a significantly longer survival (P = 0.002) than that of patients with normal or low FMI.
Survival curves according to FMI and FFM classifications are shown in Figure 2D . Groups with a shorter median survival were those with a low FFMI, either with normal FM (sarcopenic) or high FM (sarcopenic obesity). Patients with a low FFMI and high FMI (ie, sarcopenic obesity) showed the shortest median survival (0.20 y; range: 0.06-0.34 y), whereas patients with a normal FFMI and high FMI (obesity) showed the longest median survival (2.61 y; range: 0.23-3.20 y).
Results of the Cox regression analysis are shown in Table 4 . In the bivariate analysis, patients with a low FFMI (sarcopenia) showed a significantly higher mortality rate than that of patients who had a normal FFMI (HR: 6.39; 95% CI: 3.54, 11.54), and a high compared with normal or low FMI was protective (HR: 0.47; 95% CI: 0.29, 0.77). However, when results were adjusted by controlling for potential confounding variables, the effect of a high FMI on mortality was no longer significant (HR: 1.51; 95% CI: 0.58, 3.92). In contrast, a low FFMI continued to be an independent risk factor for a higher mortality rate (HR: 4.35; 95% CI: 2.11, 8.99). Patients with a low FFMI showed a 4.35 higher risk of mortality (P , 0.001) compared with that for patients with a normal FFMI.
DISCUSSION
The first publication that introduced the term "obesity paradox" can be dated back to 2002 (15) . Since then, .200 articles have been published on this topic describing clinical or surgical studies (16) (17) (18) (19) (20) (21) (22) (23) . However, in most of these studies, only BMI $30 was used as an index of obesity (8) .
Obesity is a condition in which an abnormal or excessive fat accumulation can lead to health impairments (24) . Obesity, as defined by BMI, may be misleading because weight adjusted for height is not a specific marker of total body fat or abnormal fat accumulation (25) . Other available indexes of obesity, such as skinfold thickness and waist circumference, may be used to assess risk of unfavorable health outcomes. Casas-Vara et al (26) studied older patients with congestive heart failure and assessed BMI along with other nutritional measures, such as arm-muscle area, triceps skinfold thickness, handgrip strength, and plasma proteins. Patients considered obese (BMI $30) showed a better prognosis than did other BMI groups. However, there was no association between skinfold thickness above the 95th percentile, which is another marker of body fatness, and better survival. Obese subjects were younger and had a better nutritional status and anthropometric and laboratory measures than did nonobese subjects. Thus, obesity defined by higher BMI appears to only be a marker of a better nutritional status than for nonobese subjects with a worse prognosis (26) . As shown in this study, BMI did not identify most of the patients with excess FM. Patients with excess FM were misclassified as overweight or even normal weight according to BMI criteria. This misclassification can explain the controversial results of the obesity paradox reported in studies that used BMI as a classification criterion for obesity.
In this study, body composition was estimated by using BIA. Although other body-composition techniques are considered the gold standard (eg, dual-energy X-ray absorptiometry and MRI), BIA is still a reliable and portable method for body-composition assessment in clinical practice and allows for a better understanding of body compartments. Furthermore, BIA has been proven as a useful prognostic tool in several conditions (12) . The exploration of the value of FFM depletion (ie, sarcopenia) associated with malnutrition, aging, or cachexia as a risk factor in cancer patients is of crucial interest. Sarcopenia is frequently associated with wasting syndromes such as cancer, where the combination of decreased nutrient intake and mild to moderate chronic inflammation (chronic disease-related malnutrition) have an impact on muscle anabolism and catabolism, which ultimately determines the loss of skeletal muscle mass and function over the course of the illness (27) .
In our study, sarcopenia, as defined by a low FFMI, was an independent risk factor for higher mortality, even after adjustments were made for other well-recognized risk factors, including BMI, in the multivariate Cox analysis. Previous studies have also shown that low skeletal muscle mass predicts toxicity and the drug concentration in cancer patients receiving chemotherapy (28, 29) . In patients with cirrhosis with or without hepatocellular carcinoma, sarcopenia was a strong and independent risk factor for mortality, even after controlling for other factors related to disease severity (30, 31) . In other clinical situations, such as in hemodialysis patients, weight loss, skeletal muscle mass loss, and decreasing serum concentrations of creatinine, a marker of a skeletal muscle mass, were predictors of higher mortality rates (32) . In agreement with our results, KalantarZadeh et al concluded that skeletal muscle mass is a better determinant of mortality rates than BMI. As illustrated in our study, a sharper decline was observed in FFMI curves ( Figure 2B ) than BMI curves (Figure 2A) .
When both compartments were taken into account (FFMI and FMI), the 2 groups with sarcopenia (even with a normal or high FMI) had the shortest survival time. Most research on risk of outcomes associated with body composition has been focused on markers of obesity (25) . Low skeletal muscle mass is also an important predictor of mortality, as was shown in our study. Excess FM had no protective effect in the presence of low skeletal muscle mass because the shortest survival time was observed in the sarcopenic obese group. The current results are in accordance with Prado et al (29) who reported that sarcopenic obesity is an independent predictor of survival in a sample of patients with solid tumors of the respiratory and gastrointestinal tracts. These findings combined suggest that FM only acts as a protective factor when FFM is of suitable size (normal FFMI and high FMI).
Sarcopenic obesity is often observed in the presence of malignancy, rheumatoid arthritis, and aging (33) . However, there is still no consensus on the definition low skeletal muscle mass or high FM (34) . Recently, 8 sarcopenic obesity definitions were compared in a systematic review by using data from the NHANES (35) . The authors reported a prevalence of sarcopenic obesity that ranged from 4% to 12% depending to the methodology used for its assessment or studied population (36) .
In most instances, BMI alone does not identify sarcopenic obesity because shifts (gains and losses) in the FM and FFM compartments can result in an unchanged and normal BMI, as illustrated in our study (12) . In addition to being a hidden condition, sarcopenic obesity has been associated with worse clinical outcomes than for sarcopenia or obesity alone, including prolonged hospitalizations (12) , greater risk of postoperative infections (37) , and higher mortality rates (29) .
The current findings have suggested that an increase in body fat should not be encouraged as promoting survival advantages. An increased FM will be of benefit only when it occurs alongside normal or increased FFM and associated with improvements in nutritional reserve. Therefore, nutritional therapy in patients with chronic diseases should focus on the preservation of FFM with an adequate amount of calories, protein, and exercise while avoiding bed rest to the extent possible (38) . As concluded by KalantarZadeh et al (8) , short-term death risk that is attributable to the combination of malnutrition and inflammation, which is present in wasting diseases, may overwhelm long-term risk of obesity. Thus, our efforts should be to recognize wasting diseases and intervene with nutritional measures early in the process to prevent losses in FFM and improve survival.
In conclusion, our findings indicated that the obesity paradox occurs in cancer patients only when obesity is defined by BMI but not when defined by BIA-assessed body composition. FM may only be considered a protective factor in the presence of normal FFM. Under these circumstances, FM stands as a marker of better nutritional reserves and can be associated with longer survival. When body fat and FFM were both considered, excess FM was not an isolated protective factor for longer survival, with sarcopenic obese patients presenting with the shortest survival. In this study of cancer patients, we showed that a decrease in FFM (sarcopenia) is a significant risk factor for mortality, even after we controlled for other risks factors such as tumor stage and type of chemotherapy. The identification of FFM depletion, isolated (sarcopenia) or combined to obesity (sarcopenic obesity), should be identified earlier in the disease trajectory with interventions to follow. This measure is likely to promote improved clinical outcomes.
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